Alzheimer’s disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer’s disease is known to be the sixth leading cause of death in the US. Presently, more than 6 million Americans of all ages are living with Alzheimer’s and this number is projected to reach around 13 million by 2050. In 2020, the healthcare burden associated with the disease was estimated to be around USD 305 billion.
The primary set of symptoms associated with Alzheimer’s disease include disorientation, personality / behavioral changes, confusion about events / time / place and severe memory loss. In addition, the people suffering with this disease are known to face difficulty in speaking, swallowing and walking. As the disease progresses, the aforementioned symptoms become more pronounced and also trigger brain cell death.
Given the socioeconomic burden associated with Alzheimer’s, pharmaceutical players have been on the lookout for reliable diagnostic tests and effective treatment alternatives that can slow the progression of this disease.
Presently, over 160 companies, based in different regions of the world, have taken initiatives to develop drug therapies for Alzheimer’s disease; the market is characterized by a mix of well-established and small firms.
Partnerships and Collaborations
Multiple partnerships have been forged by various established players and start-ups in this domain in order to expand their research efforts and respective product portfolios.
In addition, in the past few years, several organizations have extended financial support to aid the ongoing research and development activities in this domain.
Intellectual Property Landscape
The intellectual property associated with Alzheimer’s disease has also increased, as numerous patents related to the drug molecules have been filed by / granted to various organizations.
Future Evolution of Alzheimer’s Disease Market
The overall market opportunity for Alzheimer’s disease therapies is likely to be distributed across different types of treatments, symptomatic indication and key geographical regions.
Several stakeholders in the pharmaceutical industry are engaged in efforts to develop various types of disease modifying interventions and drug / therapy candidates that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital and other strategic investors. In the coming years, the market is anticipated to grow at a significant pace as more novel solutions clear clinical evaluation and get commercialized.
For more details on this emerging domain, check out the following report: